(NASDAQ: CUE) Cue Biopharma's forecast annual revenue growth rate of 20.99% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.67%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.07%.
Cue Biopharma's revenue in 2026 is $27,466,000.On average, 2 Wall Street analysts forecast CUE's revenue for 2026 to be $3,287,914, with the lowest CUE revenue forecast at $3,190,253, and the highest CUE revenue forecast at $3,418,128. On average, 2 Wall Street analysts forecast CUE's revenue for 2027 to be $3,287,914, with the lowest CUE revenue forecast at $3,190,253, and the highest CUE revenue forecast at $3,418,128.
In 2028, CUE is forecast to generate $179,028,523 in revenue, with the lowest revenue forecast at $3,190,253 and the highest revenue forecast at $368,832,288.